COMPOUND PROFILE / PROTEINS & BIOLOGICS
IGF-1.
Research draftIGF-1 is an endogenous growth factor; recombinant human IGF-1 is called mecasermin.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Identity and evidence review notes
Confirm exact identity, sequence, alias or formulation before attaching product-specific evidence.
Overview
IGF-1 is an endogenous growth factor; recombinant human IGF-1 is called mecasermin.
Mechanism
It activates IGF-1 receptors involved in growth and metabolism.
Human research
Evidence for regulated recombinant products is disease-specific. It cannot establish benefits of unidentified research IGF-1 products.
Preclinical & other research
Cell and animal studies examine growth signalling and tissue responses.
Safety & unknowns
Hypoglycaemia and inappropriate growth signalling are important concerns.
Regulatory status
Mecasermin has a defined prescription indication. Native IGF-1 evidence must not be transferred to IGF-1 LR3.
Reported use & evidence
The supplied IGF-1 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.